Lannett Company, Inc. (NYSE: LCI) announced plans to co-develop a generic insulin pharmaceutical product for the U.S. market with its strategic partner in China, YiChang HEC ChangJiang Pharmaceutical Co., Ltd, an HEC Group company. The product is ...
more»